GSK pens $1.3B Hutchmed deal for early-stage KRAS-EGFR cancer asset Read more →

Ultragenyx fails phase 3 Angelman test, plots ‘significant expense reductions’ Read more →

Fortrea boosts early-phase CRO platform with $45M acquisition of Worldwide division Read more →